Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Operating Expenses (2019 - 2025)

Harmony Biosciences Holdings' Other Operating Expenses history spans 7 years, with the latest figure at -$6.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 121.67% year-over-year to -$6.0 million; the TTM value through Dec 2025 reached $119.5 million, up 7.75%, while the annual FY2025 figure was $119.5 million, 7.75% up from the prior year.
  • Other Operating Expenses for Q4 2025 was -$6.0 million at Harmony Biosciences Holdings, down from $29.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $65.2 million in Q2 2025 and bottomed at -$6.0 million in Q4 2025.
  • The 5-year median for Other Operating Expenses is $23.0 million (2023), against an average of $23.8 million.
  • The largest YoY upside for Other Operating Expenses was 128.83% in 2025 against a maximum downside of 121.67% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $19.1 million in 2021, then rose by 10.29% to $21.1 million in 2022, then increased by 27.57% to $26.9 million in 2023, then increased by 2.66% to $27.6 million in 2024, then tumbled by 121.67% to -$6.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Other Operating Expenses are -$6.0 million (Q4 2025), $29.5 million (Q3 2025), and $65.2 million (Q2 2025).